ERAS — Erasca, Inc. stock price, charts and financials

Latest market price

17.84

-0.31-1.71%

Overview Short InterestFilings

ERASQT91Erasca, Inc.·NASDAQ

Overview Short InterestFilings

17.84-1.71%

News

Down 1.7% — ERASCA LEAD PLAINTIFF DEADLINE AUGUST 10th: Bragar Eagel & Squire, P.C. Reminds Erasca, Inc. (ERAS) Investors with Large Losses to Contact the Firm Regarding their Rights (globenewswire.com).

Medium confidence

Loading chart...

Signal & projected range

Analyst consensus risingHistorical pattern — not a prediction

Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)

Horizon

Unlock the projected rangeSee where this setup landed historically — with Premium.

Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →

CGON-2.87%$69.15 CNTA+0.00%$40.50 BLTE-2.41%$154.79 MIRM-1.28%$104.59 XENE-0.65%$62.26 COGT-0.18%$38.86 RYTM+3.56%$102.78 LGND+1.56%$292.04

Snapshot

Index	-	P/E	-	EPS (ttm)	-	Insider Own	11.80%	Shs Outstand	347.13M	Perf Week	-5.02%

Market Cap	6.30B	Forward P/E	-	EPS next Y	-0.55	Insider Trans	-0.24%	Shs Float	208.78M	Perf Month	1.28%

Enterprise Value	6.30B	PEG	0.17	EPS next Q	-	Inst Own	-	Short Float	14.74%	Perf Quarter	70.42%

Income	-316.28M	P/S	0.00	EPS this Y	-	Inst Trans	-	Short Ratio	4.44	Perf Half Y	76.04%

Sales	0.00	P/B	14.04	EPS next Y	41.58%	ROA	-60.06%	Short Interest	30.77M	Perf YTD	387.90%

Book/sh	-	P/C	-	EPS next 5Y	-	ROE	-77.01%	52W High	23.87 -25.25%	Perf Year	1070.97%

Cash/sh	-	P/FCF	-	EPS past 3/5Y	-	ROIC	-32.56%	52W Low	1.31 1264.66%	Perf 3Y	617.39%

Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-	Gross Margin	0.00%	Volatility	6.30% 6.55%	Perf 5Y	-5.07%

Dividend TTM	-	EV/Sales	0.00	EPS Y/Y TTM	-34.78%	Oper. Margin	0.00%	ATR (14)	1.23	Perf 10Y	-

Dividend Ex-Date	-	Quick Ratio	9.52	Sales Y/Y TTM	-	Profit Margin	0.00%	RSI (14)	51.27	Recom	2.18

Dividend Gr. 3/5Y	-	Current Ratio	9.52	EPS Q/Q	-445.45%	SMA20	-4.06%	Beta	0.68	Target Price	22.83

Payout	0.00%	Debt/Eq	0.12	Sales Q/Q	-	SMA50	13.52%	Rel Volume	0.52	Prev Close	18.15

Employees	103	LT Debt/Eq	0.13	Earnings	Aug 11	SMA200	66.42%	Avg Volume	5.23M	Price	17.84

IPO Date	Jul 16, 2021	Option/Short	Yes / Yes	EPS/Sales Surpr.	-475.32% -	Net Debt/EBITDA	0.00	Volume	2,696,631	Change	-1.71%

Analyst Ratings

Date	Action	Analyst	Rating	Target
Jul-20-26	Reiterated	Morgan Stanley	Equal Weight	$10 → $21
Jul-14-26	Reiterated	Jefferies		$6.00 → $24
Jul-14-26	Reiterated	HSBC		$20
Jun-04-26	Reiterated	Wolfe Research		$16
Jun-04-26	Upgrade	B of A Securities	Underperform → Neutral
May-12-26	Reiterated	Mizuho	Outperform	$5.00 → $26
Apr-27-26	Reiterated	Stifel Nicolaus		$20 → $30
Mar-10-26	Reiterated	Stifel Nicolaus		$10 → $20
Jan-27-26	Reiterated	Guggenheim	Buy	$5.00 → $12
Jan-26-26	Reiterated	Morgan Stanley	Equal Weight	$4.00 → $10

Latest News

Today

Today06:27PM

ERASCA LEAD PLAINTIFF DEADLINE AUGUST 10th: Bragar Eagel & Squire, P.C. Reminds Erasca, Inc. (ERAS) Investors with Large Losses to Contact the Firm Regarding their Rightsglobenewswire.com

05:28PM

ERAS 1-WEEK DEADLINE ALERT: HBSS Investigating Pending Claims Against Erasca (ERAS) in Securities Class Action Arising from Patent Litigation and Patient Safety Risksglobenewswire.com

03:31PM

Erasca, Inc. Notice of August 10, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadlinenewsfilecorp.com

12:30PM

Kaplan Fox Notifies Erasca, Inc. (ERAS) Investors of an Upcoming Lead Plaintiff Deadline on August 10, 2026newsfilecorp.com

02:02AM

Erasca, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - ERASprnewswire.com

02:02AM

ERAS Investors Have Opportunity to Lead Erasca, Inc. Securities Fraud Lawsuit with SBS Lawprnewswire.com

Aug-02-26

Aug-02-2610:16PM

ERASCA DEADLINE: ROSEN, A LONGSTANDING FIRM, Encourages Erasca, Inc. Investors to Secure Counsel Before Important August 10 Deadline in Securities Class Action - ERASnewsfilecorp.com

02:36PM

ERASCA DEADLINE: ROSEN, REGARDED INVESTOR COUNSEL, Encourages Erasca, Inc. Investors to Secure Counsel Before Important August 10 Deadline in Securities Class Action – ERASglobenewswire.com

01:13PM

ERAS SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Reminds Erasca (ERAS) Investors of Securities Class Action Lawsuit Deadline on August 10, 2026newsfilecorp.com

Aug-01-26

Aug-01-2610:15PM

ERASCA DEADLINE: ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Erasca, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important August 10 Deadline in Securities Class Action - ERASnewsfilecorp.com

Jul-31-26

Jul-31-2602:41PM

ERAS AUGUST 10, 2026 DEADLINE: Erasca, Inc. Investors Have Opportunity to Lead Shareholder Class Action Lawsuit - HBSSprnewswire.com

01:43PM

Erasca, Inc. Notice of August 10, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadlinenewsfilecorp.com

12:00PM

Bronstein, Gewirtz & Grossman LLC Urges Erasca, Inc. Investors to Act: Class Action Filed Alleging Investor Harmglobenewswire.com

11:39AM

ERAS INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Erasca (ERAS) Investors of Securities Class Action Lawsuit Deadline on August 10, 2026newsfilecorp.com

10:28AM

Robbins LLP Reminds Erasca, Inc. Investors of the Pending Lead Plaintiff Deadline in the Securities Fraud Class Action; Contact the Firm to Learn About Your Rightsglobenewswire.com

Company

Erasca, Inc. is a biopharmaceutical company in the clinical development stage, primarily focused on identifying, advancing, and commercializing therapeutic solutions for malignancies propelled by the RAS/MAPK pathway. The firm's pipeline features several key experimental drugs: ERAS-007, an orally administered ERK1/2 inhibitor designed to address non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor targeting patients with advanced or metastatic solid tumors. Additionally, Erasca is progressing ERAS-801, an EGFR inhibitor capable of penetrating the central nervous system, intended for recurrent glioblastoma multiforme. The company was founded in 2018 and maintains its headquarters in San Diego, California.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements

DataTimeframe

Line Item (USD, M)	FY 2025 12/31/2025	FY 2024 12/31/2024	FY 2023 12/31/2023	FY 2022 12/31/2022	FY 2021 12/31/2021	FY 2020 12/31/2020	FY 2019 12/31/2019
Total Revenue	0	0	0	0	0	0	0
Cost of Goods Sold Incl. D&A	3	0	4	3	1	0	0
Gross Profit	-3	0	-4	-3	-1	0	0
Selling, General and Administrative Excl. Other	39	42	38	33	23	8	4
Research and Development	93	115	104	112	74	101	10
Other Operating Expense	-4	23	-4	100	27	0	-1
Operating Income	-131	-180	-142	-247	-125	-109	-13
Interest Expense	0	0	0	201	0	0	0
Unusual Expense	—	—	—	—	—	—	—
Non-Operating Income (Expense)	7	18	16	206	2	8	1
Net Income Before Taxes	-125	-162	-125	-243	-123	-102	-12
Income Taxes	0	0	0	0	0	0	0
Consolidated Net Income	-125	-162	-125	-243	-123	-102	-12
Net Income From Continuing Operations	-125	-162	-125	-243	-123	-102	-12
Net Income	-125	-162	-125	-243	-123	-102	-12
EPS (Recurring)	-0.44	-0.69	-0.83	-1.99	-1.03	-0.85	-0.10
EPS (Basic, Before Extraordinaries)	-0.44	-0.69	-0.83	-1.99	-1.03	-0.85	-0.10
EPS (Diluted)	-0.44	-0.69	-0.83	-1.99	-1.03	-0.85	-0.10
EBITDA	-121	-153	-121	-240	-122	-37	-13
Other After Tax Adjustments	—	—	—	—	—	—	—
Stock Option Compensation Expense	—	—	—	—	—	—	—
Price To Earnings Ratio	—	—	—	—	—	—	—
Price To Sales Ratio	—	—	—	—	—	—	—
Gross Margin	—	—	—	—	—	—	—
Operating Margin	—	—	—	—	—	—	—
Net Margin	—	—	—	—	—	—	—
Shares Outstanding	284	234	150	122	119	119	119
Market Capitalization	1,056	587	320	526	1,854	—	—
Operating Lease Expense	—	—	—	—	—	—	—

Unlock full historical data

See years of past statements with Premium.

Unlock with Premium

Insider Trading Volume

Insider Trading

Insider	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Garner Ebun	Chief Legal Officer	Apr 01 '26	Option Exercise	1.70	80,000	136,000	105,076	Apr 03
Garner Ebun	Chief Legal Officer	Apr 01 '26	Sale	16.40	80,000	1,312,000	25,076	Apr 03
Morris Shannon	Chief Medical Officer	Mar 04 '26	Option Exercise	1.70	20,000	34,000	20,000	Mar 06
Morris Shannon	Chief Medical Officer	Mar 04 '26	Sale	15.04	20,000	300,760	0	Mar 06
Morris Shannon	Chief Medical Officer	Mar 04 '25	Option Exercise	1.70	20,000	34,000	515,800	Mar 06
Garner Ebun	General Counsel & Corp. Sec.	Jan 07 '26	Option Exercise	1.70	120,000	204,000	145,076	Jan 08
Garner Ebun	General Counsel & Corp. Sec.	Jan 07 '26	Sale	5.59	120,000	670,812	25,076	Jan 08
Garner Ebun	General Counsel & Corp. Sec.	Jan 07 '25	Option Exercise	1.70	120,000	204,000	360,000	Jan 08
Casdin Alexander W.	Director	May 21 '24	Buy	2.27	80,000	181,920	573,974	May 22
Start Valerie Denise Harding	Director	Dec 06 '23	Buy	1.85	10,000	18,480	20,000	Dec 08
Lim Jonathan E	Chairman & CEO	Dec 06 '23	Buy	1.72	278,150	478,418	12,899,360	Dec 06
Lim Jonathan E	Chairman & CEO	Dec 05 '23	Buy	1.69	721,850	1,217,761	12,899,360	Dec 06
Casdin Alexander W.	Director	Dec 04 '23	Buy	1.66	30,000	49,785	493,974	Dec 04
Lim Jonathan E	Chairman & CEO	Oct 05 '23	Buy	2.03	1,000,000	2,026,000	19,456,216	Oct 10
Lim Jonathan E	Chairman & CEO	Jun 08 '23	Buy	2.75	100,000	275,000	18,396,216	Jun 08

open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR

QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.